Monitoring patients with sickling disorders who have received hydroxyurea or transfusion therapy
Lavender (EDTA), 4mL
Yellow ACD (A or B)
Dk green heparin (Li or Na), no gel
Yellow ACD (A or B)
Dk green heparin (Li or Na), no gel
Refrigerated (preferred) - 10 days
Ambient - NO
Frozen - NO
Capillary electrophoresis
Hemoglobin A
1 - 30 days: 5.9 - 77.2%
1 - 2 months: 7.9-92.4%
3 - 5 months: 54.7 - 97.1%
6 - 8 months: 80.0 - 98.0%
9 - 12 months: 86.2 - 98.0%
13 - 17 months: 88.8 - 98.0%
18 - 23 months: 90.4 - 98.0%
≥ 24 months: 95.8 - 98.0%
Hemoglobin A2
1 - 30 days: 0.0 - 2.1%
1 - 2 months: 0.0 - 2.6%
3 - 5 months: 1.3 - 3.1%
≥ 6 months: 2.0 - 3.3%
Hemoglobin F
1 - 30 days: 22.8 - 92.0%
1 - 2 months: 7.6 - 89.8%
3 - 5 months: 1.6 - 42.2%
6 - 8 months: 0.0 - 16.7%
9 - 12 months: 0.0 - 10.5%
13 - 17 months: 0.0 - 7.9%
18 - 23 months: 0.0 - 6.3%
≥ 24 months: 0.0 - 0.9%
This test is intended for monitoring purposes, such as the increase in hemoglobin F (Hb F) after therapy, or the levels of hemoglobin variants after transfusion. The HPFH / Hemoglobin F, Red Cell Distribution, Blood test is a flow cytometry assay that determines the distribution of Hb F within red blood cells.